Cuprina Holdings is trading 6.5% down at $1.72, with no confirmed company-specific catalyst for the October 30 decline. - No new company-specific announcement explaining the decline surfaced in the search. - The Singapore-clinic acquisition was announced October 2 and is expected to close by November 1; it is prior context, not a clear new catalyst. - U.S. markets faced technology-led selling and defensive positioning during Friday trading, but no report directly linked that weakness to Cuprina’s decline.